HedgeChatter

  • Home /
  • Tag Archives

PCYC

1:20 pm Pharmacyclics confirms FDA approval of IMBRUVICA (ibrutinib) as a single agent for patients with chronic lymphocytic leukemia who have received at least one prior therapy

moreView todays social media effects on PCYCView the latest stocks trending across Twitter. Click to view dashboardSee who Pharmacyclics is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on 1:20 pm Pharmacyclics confirms FDA approval of IMBRUVICA (ibrutinib) as a single agent for patients with chronic lymphocytic leukemia who have received at least one prior therapy read more

FDA clears Pharmacyclics drug for new cancer use

moreView todays social media effects on PCYCView the latest stocks trending across Twitter. Click to view dashboardSee who Pharmacyclics is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on FDA clears Pharmacyclics drug for new cancer use read more

U.S. Food and Drug Administration Approves IMBRUVICAâ„¢ (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

[PR Newswire] – SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ — Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA â„¢ (ibrutinib) as a single agent … moreView todays social media effects on PCYCView the latest stocks trending across Twitter. Click to view dashboardSee who Pharmacyclics is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on U.S. Food and Drug Administration Approves IMBRUVICAâ„¢ (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy read more

Pharmacyclics, J&J Win Wider Use of Blood Cancer Drug

moreView todays social media effects on PCYCView the latest stocks trending across Twitter. Click to view dashboardSee who Pharmacyclics is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on Pharmacyclics, J&J Win Wider Use of Blood Cancer Drug read more

PropThink: Earnings Are Hardly the Focus of Pharmacyclics’ Fiscal 1Q13 Financial Report

[ACN Newswire] – By Jake KingIn one of Monday’s notable volume abnormalities, shares of Pharmacyclics (NASDAQ:PCYC) have exchanged hands at more than five times average volume, and PCYC is down 11% following the company’s … moreView todays social media effects on PCYCView the latest stocks trending across Twitter. Click to view dashboard […]

November 5, 2012 Bystocknews , Comments Off on PropThink: Earnings Are Hardly the Focus of Pharmacyclics’ Fiscal 1Q13 Financial Report read more